Boston Scientific falls after discontinuing heart device, FDA approval pursuit

Shares of medical device maker Boston Scientific BSX.N fall 2% to $103 premarket

BSX says it is discontinuing worldwide sales of its experimental heart device and will no longer seek US FDA approval in the country or other regions

Co says the decision was made due to increased regulatory requirements

Co also says it expects to meet its Q2 and FY25 sales and adjusted earnings forecast

As of last close, stock up ~19% YTD